FDA approves Tazverik (tazemetostat), first treatment option for patients with very rare epithelioid sarcoma
US Food and Drug Administration - FDA
US Food and Drug Administration
23 January 2020
Approval was based on results of a study (n=62) which found 800 mg twice a day provided 15% overall response rate, with 1.6% of patients having a complete response and 13% having a partial response.